Confronto
Degarelix vs. Semax
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
214766-78-6
80714-61-0
Peso molecolare
1632.3 g/mol
813.92 g/mol
Emivita
1320 h
0.3 h
Sequenza
Ac-D-2Nal-D-4Cpa-D-3Pal-Ser-4Aph(Hor)-D-4Aph(Cbm)-Leu-Ilys-Pro-D-Ala-NH2Met-Glu-His-Phe-Pro-Gly-ProMeccanismo d'azione
Degarelix
Degarelix is a competitive GnRH receptor antagonist. It binds reversibly and immediately to the pituitary GnRH receptors and blocks their activation. This rapidly suppresses the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn lowers testosterone production in the testes. Unlike GnRH agonists (e.g., leuprorelin), which first cause a transient stimulation with a testosterone surge (flare), this direct antagonism lacks the initial stimulation phase, so testosterone declines without a preceding rise. This mechanism underlies the literature-described use in hormone-dependent prostate cancer.
Semax
Semax is a tetracosactide fragment analog without hormonal activity at MC2R. Proposed mechanisms include elevation of BDNF and NGF in hippocampus and striatum (in animal models), modulation of dopamine metabolism, and neuroprotective effects via anti-apoptotic pathways. A clear primary receptor is not established.
Base di evidenze
Evidenza più alta
RCT sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
4
2
Effetti registrati
4
3
Contraddizioni aperte
1
1
Eventi avversi documentati
2
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Degarelix and Semax?
- Degarelix is classified as "Ricerca (altro)", while Semax is classified as "Ricerca (altro)". Degarelix: Degarelix (trade name Firmagon) is a synthetic decapeptide and a gonadotropin-releasing hormone (GnRH) receptor antagonist. Unlike GnRH agonists, it blocks the receptor directly and does not trigger an initial testosterone surge (flare). It is an approved prescription medicine for the treatment of advanced, hormone-dependent prostate cancer. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. Semax: Synthetic heptapeptide derived from the N-terminal fragment of adrenocorticotropic hormone (ACTH 4-10). Approved in Russia for ischaemic stroke, cognitive function and ADHD in children. Western phase-3 trials absent. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Degarelix or Semax?
- The highest available evidence level is "RCT sull'uomo" for Degarelix and "Studio sull'uomo" for Semax. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Degarelix and Semax in Germany and the United States?
- Germania: Degarelix — Su prescrizione, Semax — Non approvato. Stati Uniti: Degarelix — Su prescrizione, Semax — Non approvato. These are factual summaries with source and review date on the individual pages.